MicroStrategy
MSTR
NVIDIA
NVDA
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
US Stock MarketDetailed Quotes
CABA Cabaletta Bio
- 2.380
- +0.070+3.03%
Close Dec 20 16:00 ET
- 2.400
- +0.020+0.84%
Post 20:01 ET
116.33MMarket Cap-1.10P/E (TTM)
2.510High2.230Low1.84MVolume2.270Open2.310Pre Close4.41MTurnover4.43%Turnover RatioLossP/E (Static)48.88MShares26.35052wk High0.67P/B98.93MFloat Cap1.76052wk Low--Dividend TTM41.57MShs Float26.350Historical High--Div YieldTTM12.12%Amplitude0.590Historical Low2.395Avg Price1Lot Size
About Cabaletta Bio Company
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
Company Profile
SymbolCABA
Company NameCabaletta Bio
Listing DateOct 25, 2019
Issue Price11.00
Founded2017
CEODr. Steven Nichtberger,M.D.
MarketNASDAQ
Employees103
Fiscal Year Ends12-31
Address2929 Arch Street,Suite 600
CityPhiladelphia
ProvincePennsylvania
CountryUnited States of America
Zip Code19104
Phone1-267-759-3100
Websitehttp://www.cabalettabio.com
Company Executives
- Name
- Position
- Salary
- Dr. Steven Nichtberger,M.D.
- Chairman of the Board, President and Chief Executive Officer
- 4.81M
- Arun Das, M.D.
- Chief Business Officer
- --
- Anup Marda, M.B.A.
- Chief Financial Officer and Principal Accounting Officer
- --
- David J. Chang, M.D.,M.P.H.
- Chief Medical Officer
- 2.10M
- Dr. Gwendolyn K. Binder-Scholl, M.D.,PhD
- President, Science and Technology
- 2.34M
- Richard C. Henriques, M.B.A.
- Independent Director
- 259.20K
- Mark Simon, M.B.A.
- Independent Director
- 260.15K
- Shawn Cline Tomasello, M.B.A.
- Independent Director
- 509.94K
- Catherine Bollard, M.D.
- Independent Director
- 255.43K
- Dr. Scott C. Brun, M.D.
- Independent Director
- 255.83K
- Michael Gerard, J.D.
- General Counsel and Secretary
- --
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.